Brief: Larimar Therapeutics Announces Positive Initial Data From Ongoing Long-Term Open Label Extension Study

Larimar Therapeutics

16/12/2024 12:25

Dec 16 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM
ONGOING LONG-TERM OPEN LABEL EXTENSION STUDY & PROGRESS ACROSS
NOMLABOFUSP PROGRAM FOR FRIEDREICH’S ATAXIA
    * LARIMAR THERAPEUTICS INC - NOMLABOFUSP 25 MG WELL
TOLERATED IN
14 PARTICIPANTS FOR UP TO 260 DAYS
    * LARIMAR THERAPEUTICS INC - BLA SUBMISSION TARGETED FOR 2H
2025
FOR POTENTIAL ACCELERATED APPROVAL
    * LARIMAR THERAPEUTICS INC: PROJECTED RUNWAY INTO Q2 OF 2026

Source text:  ID:nGNX5jYKxP 
Further company coverage:  LRMR.O